An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
This research study is an extension of an earlier study and aims to understand the long-term safety and how a medicine called Votoplam works in people living with Huntington's disease. If you took part in the first study (study PTC518-CNS-002-HD) and finished the treatment period, you might be able to join this one. All participants in this extended study will receive active Votoplam. If you took Votoplam in the first study, you'll continue with the same dose. If you received a dummy medicine (placebo) before, you'll now be given Votoplam at a specific dose. Doctors will monitor how your body responds to the medicine over an additional 54 months (about 4 and a half years). This helps researchers learn more about Votoplam's effects over a longer period.
Auf einen Blick
Worum geht es in dieser Studie?
Huntington's disease is a condition that affects the brain and can lead to changes in movement, thinking, and mental health. There isn't a cure yet, so researchers are always looking for new treatments to help manage the symptoms and slow down the disease's progress.
This study is an important next step in understanding a medicine called Votoplam. If you've already been part of a previous study testing Votoplam (called Study PTC518-CNS-002-HD and identified as NCT05358717), and you completed the treatment part of that study, this new study offers a chance to continue receiving Votoplam. The main aim is to see how safe Votoplam is over a much longer period and how it affects the body and the disease.
By continuing to observe participants for an extra 54 months, researchers hope to gather valuable information about the long-term effects of Votoplam. This kind of extended study is crucial for understanding how a new medicine works over time and helps scientists determine if it could be a helpful treatment for people with Huntington's disease in the future.
Wichtige Erkenntnisse
- This study is an extension of a previous Votoplam trial for Huntington's disease.
- It aims to understand the long-term safety and effects of Votoplam.
- Only participants who completed the previous study can join.
- All participants in this study will receive active Votoplam.
- The study involves regular check-ups over about 4.5 years.
- Die Teilnahme ist freiwillig, und Sie können jederzeit zurücktreten.
Wer könnte berechtigt sein?
To be considered for this study, you must have already completed the full treatment period of the previous Votoplam study (known as Study PTC518-CNS-002-HD). This means you would have finished all the medicines and check-ups required for that earlier study.
If you did not complete the treatment period in the previous study, unfortunately, you would not be able to join this particular extension study. This study is specifically designed for those who have already participated in and completed the initial research.
Please remember that even if you meet these main criteria, there might be other specific reasons why you could or could not join. Your study doctor can give you all the details and help you understand if this study is right for you.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Did I complete the treatment part of the previous Votoplam study (PTC518-CNS-002-HD)?
- Am I willing to have regular hospital visits and check-ups for about 4.5 years?
- Am I comfortable with receiving Votoplam?
- Am I at least 25 years old?
- Do I have Huntington's Disease?
Was beinhaltet die Teilnahme?
If you join this study, you will continue to receive the study medicine, Votoplam, over an extra 54 months. If you received Votoplam in the previous study, you'll continue with the same dose. If you received a dummy medicine (placebo) before, you will now be given Votoplam at a specific dose, which will be decided for you. You won't know which exact dose of Votoplam you are on, and neither will your study team, so that the results can be as fair as possible.
Over these 54 months, you will have regular visits with the study team. During these visits, doctors will perform different assessments to check your health, how you are responding to the medicine, and to see if the medicine is affecting your body in any way. These assessments might include physical exams, blood tests, and other specific tests related to Huntington's disease.
The main aim is to carefully track your progress and look at the long-term safety and effects of Votoplam over approximately four and a half years.
Potenzielle Risiken und Vorteile
Locations (24)
- Novartis UntersuchungsstelleVerifizierte PostleitzahlClayton, Australia
- Novartis UntersuchungsstelleVerifizierte PostleitzahlWestmead, Australia
- Novartis UntersuchungsstelleVerifizierte PostleitzahlInnsbruck, Österreich
- Novartis UntersuchungsstelleVerifizierte PostleitzahlOttawa, Kanada
- Novartis UntersuchungsstelleVerifizierte PostleitzahlAngers, Frankreich
- Novartis UntersuchungsstelleVerifizierte PostleitzahlMarseille, Frankreich
- Novartis UntersuchungsstelleVerifizierte PostleitzahlParis, Frankreich
- Novartis UntersuchungsstelleVerifizierte PostleitzahlBerlin, Deutschland
- Novartis UntersuchungsstelleVerifizierte PostleitzahlBochum, Germany
- Novartis UntersuchungsstelleVerifizierte PostleitzahlMünster, Germany
- Novartis UntersuchungsstelleVerifizierte PostleitzahlUlm, Germany
- Novartis UntersuchungsstelleVerifizierte PostleitzahlBologna, Italy
Häufige Fragen
Was ist das Hauptziel dieser Studie?
The main goal is to understand how safe a medicine called Votoplam is and how it affects people with Huntington's disease over a long period (about 4.5 years).
Wer kann an dieser Studie teilnehmen?
Only people who have already completed the treatment part of a previous Votoplam study (Study PTC518-CNS-002-HD) can join this extension study.
Will I know if I'm getting the actual medicine?
Yes, everyone in this extension study will receive active Votoplam. However, you and your study team usually won't know which specific dose you are receiving to keep the study fair.
How long will I be in this study?
You'll be part of this study for an additional 54 months, which is about four and a half years.
Kann ich die Studie verlassen, wenn ich meine Meinung ändere?
Yes, you are completely free to leave the study at any time, for any reason, and it will not affect your regular medical care.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.